NUVL - Nuvalent - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

4.469B

Cash

691.8M

Avg Qtr Burn

-27.85M

Short % of Float

22.55%

Insider Ownership

3.22%

Institutional Own.

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NVL-520 Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NVL-655 Details Cancer, Non-small cell lung carcinoma, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NVL-330 Details HER2-expressing cancers, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.